Literature DB >> 25391829

A fourth case of Feingold syndrome type 2: psychiatric presentation and management.

Hooman Ganjavi1, Victoria Mok Siu2, Marsha Speevak3, Penny Anne MacDonald4.   

Abstract

Feingold syndrome (FGLDS1) is an autosomal dominant disorder caused by mutations in the MYCN oncogene on the short arm of chromosome 2 (2p24.1). It is characterised by microcephaly, digital abnormalities, oesophageal and duodenal atresias, and often learning disability or mental retardation. In 2011, individuals sharing the skeletal abnormalities of FGLDS1 but lacking mutations in MYCN, were found to harbour hemizygous deletions of the MIR17HG gene on chromosome 13q31.3. These individuals share many of the characteristics of FGLDS1 except for gastrointestinal atresia. The condition was termed Feingold syndrome type 2 (FGLDS2). We describe the presentation and management of a fourth known case of FGLDS2 in an 18-year-old girl with microcephaly, short stature, mildly dysmorphic features, digital malformations and significant cognitive and psychiatric symptoms. Comparative genomic hybridisation array testing confirmed a 7.4 Mb microdeletion in chromosome region 13q31.1q.31.3 corresponding to the MIR17HG gene. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25391829      PMCID: PMC4244445          DOI: 10.1136/bcr-2014-207501

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Aripiprazole in autism spectrum disorders and fragile X syndrome.

Authors:  Craig A Erickson; Kimberly A Stigler; David J Posey; Christopher J McDougle
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  Syndrome of microcephaly, facial and hand abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay.

Authors:  M Feingold; B D Hall; Y Lacassie; M L Martínez-Frías
Journal:  Am J Med Genet       Date:  1997-03-31

Review 3.  The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.

Authors:  Shoumitro Deb; Baldeep K Farmah; Ebrahim Arshad; Tanya Deb; Meera Roy; Gemma L Unwin
Journal:  Res Dev Disabil       Date:  2014-01-07

Review 4.  Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.

Authors:  L Letterman; J S Markowitz
Journal:  Pharmacotherapy       Date:  1999-05       Impact factor: 4.705

5.  Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.

Authors:  Peter De Deyn; Dilip V Jeste; Rene Swanink; Dusan Kostic; Christopher Breder; William H Carson; Taro Iwamoto
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

Review 6.  Feingold syndrome: clinical review and genetic mapping.

Authors:  Jacopo Celli; Hans van Bokhoven; Han G Brunner
Journal:  Am J Med Genet A       Date:  2003-11-01       Impact factor: 2.802

7.  Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Authors:  David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard Mailman
Journal:  Neuropsychopharmacology       Date:  2003-05-21       Impact factor: 7.853

8.  A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.

Authors:  Joel E Streim; Anton P Porsteinsson; Christopher D Breder; René Swanink; Ronald Marcus; Robert McQuade; William H Carson
Journal:  Am J Geriatr Psychiatry       Date:  2008-07       Impact factor: 4.105

9.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.

Authors:  Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

10.  Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans.

Authors:  Loïc de Pontual; Evelyn Yao; Patrick Callier; Laurence Faivre; Valérie Drouin; Sandra Cariou; Arie Van Haeringen; David Geneviève; Alice Goldenberg; Myriam Oufadem; Sylvie Manouvrier; Arnold Munnich; Joana Alves Vidigal; Michel Vekemans; Stanislas Lyonnet; Alexandra Henrion-Caude; Andrea Ventura; Jeanne Amiel
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

View more
  6 in total

1.  Neurobehavioral Alterations in a Genetic Murine Model of Feingold Syndrome 2.

Authors:  E Fiori; L Babicola; D Andolina; A Coassin; T Pascucci; L Patella; Y-C Han; A Ventura; R Ventura
Journal:  Behav Genet       Date:  2015-05-31       Impact factor: 2.805

2.  A role for miR-19 in the migration of adult-born neurons and schizophrenia.

Authors:  Jinju Han; Fred H Gage
Journal:  Neurogenesis (Austin)       Date:  2016-12-05

3.  The Long-Term Effects of Early Life Stress on the Modulation of miR-19 Levels.

Authors:  Monica Mazzelli; Carlo Maj; Nicole Mariani; Cristina Mora; Veronica Begni; Carmine M Pariante; Marco A Riva; Annamaria Cattaneo; Nadia Cattane
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

4.  SARS-CoV-2 Airway Infection Results in Time-dependent Sensory Abnormalities in a Hamster Model.

Authors:  Randal A Serafini; Justin J Frere; Jeffrey Zimering; Ilinca M Giosan; Kerri D Pryce; Ilona Golynker; Maryline Panis; Anne Ruiz; Benjamin tenOever; Venetia Zachariou
Journal:  bioRxiv       Date:  2022-08-19

5.  Identification of compound heterozygous variants in the noncoding RNU4ATAC gene in a Chinese family with two successive foetuses with severe microcephaly.

Authors:  Ye Wang; Xueli Wu; Liu Du; Ju Zheng; Songqing Deng; Xin Bi; Qiuyan Chen; Hongning Xie; Claude Férec; David N Cooper; Yanmin Luo; Qun Fang; Jian-Min Chen
Journal:  Hum Genomics       Date:  2018-01-25       Impact factor: 4.639

6.  Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.

Authors:  Fatemeh Mirzamohammadi; Anastasia Kozlova; Garyfallia Papaioannou; Elena Paltrinieri; Ugur M Ayturk; Tatsuya Kobayashi
Journal:  Nat Commun       Date:  2018-04-10       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.